Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals.

Hyafil F, Chequer R, Sorbets E, Estellat C, Ducrocq G, Rouzet F, Alfaiate T, Regaieg H, Abtan J, Leygnac S, Milliner M, Imbert L, Burg S, Ben Azzouna R, Potier L, Laouénan C, Quintin C, Roussel R, Hartemann A, Montalescot G, Marie PY, Steg G, Le Guludec D.

J Nucl Cardiol. 2018 Dec 20. doi: 10.1007/s12350-018-01557-z. [Epub ahead of print]

PMID:
30574676
2.

Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol.

Lorenzon R, Mariotti-Ferrandiz E, Aheng C, Ribet C, Toumi F, Pitoiset F, Chaara W, Derian N, Johanet C, Drakos I, Harris S, Amselem S, Berenbaum F, Benveniste O, Bodaghi B, Cacoub P, Grateau G, Amouyal C, Hartemann A, Saadoun D, Sellam J, Seksik P, Sokol H, Salem JE, Vicaut E, Six A, Rosenzwajg M, Bernard C, Klatzmann D.

BMJ Open. 2018 Aug 30;8(8):e021037. doi: 10.1136/bmjopen-2017-021037.

3.

Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus.

Potier L, Chequer R, Roussel R, Mohammedi K, Sismail S, Hartemann A, Amouyal C, Marre M, Le Guludec D, Hyafil F.

Cardiovasc Diabetol. 2018 Jan 11;17(1):11. doi: 10.1186/s12933-017-0652-1.

4.

Factors associated with oral health-related quality of life in patients with diabetes.

Azogui-Lévy S, Dray-Spira R, Attal S, Hartemann A, Anagnostou F, Azerad J.

Aust Dent J. 2018 Jun;63(2):163-169. doi: 10.1111/adj.12577. Epub 2018 Jan 15.

PMID:
29140554
5.

A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The ANODE Study).

Hansel B, Giral P, Gambotti L, Lafourcade A, Peres G, Filipecki C, Kadouch D, Hartemann A, Oppert JM, Bruckert E, Marre M, Bruneel A, Duchene E, Roussel R.

J Med Internet Res. 2017 Nov 8;19(11):e360. doi: 10.2196/jmir.7947.

6.

Higher parathyroid hormone levels are associated with increased below-the-knee arterial calcification in type 2 diabetes.

Mary A, Hartemann A, Brazier M, Aubert CE, Kemel S, Salem JE, Cluzel P, Liabeuf S, Massy Z, Mentaverri R, Bourron O, Kamel S.

Diabetes Metab. 2018 Jun;44(3):305-308. doi: 10.1016/j.diabet.2017.04.008. Epub 2017 Jun 8. No abstract available.

PMID:
28602488
7.

Fast, accurate and easy-to-teach QT interval assessment: The triplicate concatenation method.

Saqué V, Vaglio M, Funck-Brentano C, Kilani M, Bourron O, Hartemann A, Badilini F, Salem JE.

Arch Cardiovasc Dis. 2017 Aug - Sep;110(8-9):475-481. doi: 10.1016/j.acvd.2016.12.011. Epub 2017 May 11.

8.

Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?

Amouyal C, Levy P, Andreelli F, Hartemann A.

Diabetes Metab. 2018 Feb;44(1):95-96. doi: 10.1016/j.diabet.2017.03.010. Epub 2017 May 5. No abstract available.

PMID:
28483292
9.

Importance of alternative-site blood glucose testing in the diagnosis of artifactual hypoglycaemia in systemic scleroderma.

Dubourdieu V, Mosbah H, Amouyal C, Hartemann A, Andreelli F.

Diabetes Metab. 2017 Oct;43(5):490-491. doi: 10.1016/j.diabet.2017.03.003. Epub 2017 Apr 25. No abstract available.

PMID:
28389064
10.

Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.

Mary A, Hartemann A, Liabeuf S, Aubert CE, Kemel S, Salem JE, Cluzel P, Lenglet A, Massy ZA, Lalau JD, Mentaverri R, Bourron O, Kamel S.

Cardiovasc Diabetol. 2017 Feb 15;16(1):24. doi: 10.1186/s12933-017-0509-7.

11.

Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012.

Billionnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A, Jacqueminet S.

Diabetologia. 2017 Apr;60(4):636-644. doi: 10.1007/s00125-017-4206-6. Epub 2017 Feb 15.

PMID:
28197657
12.

Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes.

Lebeau G, Consoli SM, Le Bouc R, Sola-Gazagnes A, Hartemann A, Simon D, Reach G, Altman JJ, Pessiglione M, Limosin F, Lemogne C.

Behav Processes. 2016 Nov;132:42-48. doi: 10.1016/j.beproc.2016.09.006. Epub 2016 Sep 20.

PMID:
27663668
13.

Loss of immune tolerance to IL-2 in type 1 diabetes.

Pérol L, Lindner JM, Caudana P, Nunez NG, Baeyens A, Valle A, Sedlik C, Loirat D, Boyer O, Créange A, Cohen JL, Rogner UC, Yamanouchi J, Marchant M, Leber XC, Scharenberg M, Gagnerault MC, Mallone R, Battaglia M, Santamaria P, Hartemann A, Traggiai E, Piaggio E.

Nat Commun. 2016 Oct 6;7:13027. doi: 10.1038/ncomms13027.

14.

A unique CD8(+) T lymphocyte signature in pediatric type 1 diabetes.

Hamel Y, Mauvais FX, Pham HP, Kratzer R, Marchi C, Barilleau É, Waeckel-Enée E, Arnoux JB, Hartemann A, Cordier C, Mégret J, Rocha B, de Lonlay P, Beltrand J, Six A, Robert JJ, van Endert P.

J Autoimmun. 2016 Sep;73:54-63. doi: 10.1016/j.jaut.2016.06.003. Epub 2016 Jun 16.

PMID:
27318739
15.

[COMMENTS ON FRENCH RECOMMENDATIONS ON GLYCEMIC CONTROL IN TYPE 2 DIABETES].

Hartemann A.

Rev Prat. 2015 Oct;65(8):1033-7. French.

PMID:
26749699
16.

[Treatment of type 2 diabetes].

Hartemann A.

Rev Prat. 2015 Oct;65(8):1031-2. French. No abstract available.

PMID:
26749698
17.

Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review.

Game FL, Apelqvist J, Attinger C, Hartemann A, Hinchliffe RJ, Löndahl M, Price PE, Jeffcoate WJ; International Working Group on the Diabetic Foot.

Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:154-68. doi: 10.1002/dmrr.2707. Review.

PMID:
26344936
18.

IWGDF guidance on use of interventions to enhance the healing of chronic ulcers of the foot in diabetes.

Game FL, Attinger C, Hartemann A, Hinchliffe RJ, Löndahl M, Price PE, Jeffcoate WJ; International Working Group on the Diabetic Foot.

Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:75-83. doi: 10.1002/dmrr.2700. No abstract available.

PMID:
26340818
19.

Lower-extremity arterial revascularization: Is there any evidence for diabetic foot ulcer-healing?

Vouillarmet J, Bourron O, Gaudric J, Lermusiaux P, Millon A, Hartemann A.

Diabetes Metab. 2016 Feb;42(1):4-15. doi: 10.1016/j.diabet.2015.05.004. Epub 2015 Jun 10. Review.

PMID:
26072053
20.

Treatment of chronic plantar ulcer of the diabetic foot using an irremovable windowed fibreglass cast boot: prospective study of 177 patients.

Ha Van G, Michaux C, Parquet H, Bourron O, Pradat-Diehl P, Hartemann A.

Diabetes Metab Res Rev. 2015 Oct;31(7):691-8. doi: 10.1002/dmrr.2657. Epub 2015 Jun 25.

PMID:
25941091
21.

Erratum: Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein.

Liabeuf S, Bourron O, Vemeer C, Theuwissen E, Magdeleyns E, Aubert CE, Brazier M, Mentaverri R, Hartemann A, Massy ZA.

Cardiovasc Diabetol. 2015 Jan 24;14:9. doi: 10.1186/s12933-014-0164-1. No abstract available.

22.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D.

J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.

23.

Type B Insulin-resistance syndrome: a cause of reversible autoimmune hypoglycaemia.

Bourron O, Caron-Debarle M, Hie M, Amoura Z, Andreelli F, Halbron M, Fonfrede M, Leroux G, Vigouroux C, Hartemann A.

Lancet. 2014 Oct 25;384(9953):1548. doi: 10.1016/S0140-6736(14)61833-X. No abstract available.

PMID:
25390580
24.

Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.

Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D.

Curr Diab Rep. 2014 Dec;14(12):553. doi: 10.1007/s11892-014-0553-6. Review.

PMID:
25344788
25.

Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy.

Bourron O, Aubert CE, Liabeuf S, Cluzel P, Lajat-Kiss F, Dadon M, Komajda M, Mentaverri R, Brazier M, Pierucci A, Morel F, Jacqueminet S, Massy ZA, Hartemann A.

J Clin Endocrinol Metab. 2014 Nov;99(11):4250-8. doi: 10.1210/jc.2014-1047. Epub 2014 Jul 11.

PMID:
25013993
26.

Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein.

Liabeuf S, Bourron O, Vemeer C, Theuwissen E, Magdeleyns E, Aubert CE, Brazier M, Mentaverri R, Hartemann A, Massy ZA.

Cardiovasc Diabetol. 2014 Apr 24;13:85. doi: 10.1186/1475-2840-13-85. Erratum in: Cardiovasc Diabetol. 2015;14:9. Olivier, Bourron [corrected to Bourron, Olivier].

27.

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8.

PMID:
24622415
28.

Burden of diabetic foot disorders, guidelines for management and disparities in implementation in Europe: a systematic literature review.

van Acker K, Léger P, Hartemann A, Chawla A, Siddiqui MK.

Diabetes Metab Res Rev. 2014 Nov;30(8):635-45. doi: 10.1002/dmrr.2523. Review.

PMID:
24470359
29.

Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.

Aubert CE, Michel PL, Gillery P, Jaisson S, Fonfrede M, Morel F, Hartemann A, Bourron O.

Diabetes Metab Res Rev. 2014 Nov;30(8):679-85. doi: 10.1002/dmrr.2529.

PMID:
24449227
30.

Evaluation of a 5-day education programme in type 1 diabetes: achieving individual targets with a patient-centred approach.

Halbron M, Sachon C, Simon D, Obadia T, Grimaldi A, Hartemann A.

Diabet Med. 2014 Apr;31(4):500-3. doi: 10.1111/dme.12372. Epub 2014 Jan 6.

PMID:
24299225
31.

Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study.

Bouhassira D, Letanoux M, Hartemann A.

PLoS One. 2013 Sep 13;8(9):e74195. doi: 10.1371/journal.pone.0074195. eCollection 2013.

32.

Influence of peripheral vascular calcification on efficiency of screening tests for peripheral arterial occlusive disease in diabetes--a cross-sectional study.

Aubert CE, Cluzel P, Kemel S, Michel PL, Lajat-Kiss F, Dadon M, Hartemann A, Bourron O.

Diabet Med. 2014 Feb;31(2):192-9. doi: 10.1111/dme.12309. Epub 2013 Sep 11.

PMID:
23952656
33.

Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes.

Baeyens A, Pérol L, Fourcade G, Cagnard N, Carpentier W, Woytschak J, Boyman O, Hartemann A, Piaggio E.

Diabetes. 2013 Sep;62(9):3120-31. doi: 10.2337/db13-0214. Epub 2013 May 13.

34.

Influence of peripheral arterial occlusive disease on the Neuropad(®) test performance in patients with diabetes.

Aubert CE, Le Doeuff J, Lajou J, Barthelemy O, Hartemann A, Bourron O.

Diabet Med. 2013 May;30(5):e178-84. doi: 10.1111/dme.12150. Epub 2013 Mar 13.

PMID:
23398465
35.

[How to differentiate between useful and useless drugs?].

Bergmann JF, Thervet E, Timsit J, Blacher J, Varet B, Hartemann A, Chosidow O, Mariette X, Gervais A, Amoura Z, Bruckert E, Pariente A, Vernant JP, Penformis F, Dautzenberg B, Sobel A, Guillevin L, Valla D, Leblond V, Gaudric A, Chast F, Bourdillon F, Fredenrich A, Bourgeois P, Grimaldi A.

Rev Prat. 2012 Nov;62(9):1192-5. French. No abstract available.

PMID:
23272464
36.

SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation.

Toubal A, Clément K, Fan R, Ancel P, Pelloux V, Rouault C, Veyrie N, Hartemann A, Treuter E, Venteclef N.

J Clin Invest. 2013 Jan;123(1):362-79. doi: 10.1172/JCI64052. Epub 2012 Dec 10.

37.

Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell.

Bourron O, Chebbi F, Halbron M, Saint-Martin C, Bellanné-Chantelot C, Abed A, Charbit B, Magnan C, Lacorte JM, Hartemann A.

Diabetes Care. 2012 Nov;35(11):e76. doi: 10.2337/dc12-0535. No abstract available.

38.

Interleukin-2 and type 1 diabetes: new therapeutic perspectives.

Hartemann A, Bourron O.

Diabetes Metab. 2012 Nov;38(5):387-91. doi: 10.1016/j.diabet.2012.05.006. Epub 2012 Jul 5. Review.

PMID:
22771204
39.

Specific guidelines on wound and wound-bed management 2011.

Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, Löndahl M, Price PE, Jeffcoate WJ; International Working Group on Diabetic Foot.

Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:232-3. doi: 10.1002/dmrr.2250. No abstract available.

PMID:
22271743
40.

A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes.

Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, Löndahl M, Price PE, Jeffcoate WJ.

Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:119-41. doi: 10.1002/dmrr.2246. Review.

PMID:
22271737
41.

Association of type B insulin resistance and type 1 diabetes resulting in ketoacidosis.

Bourron O, Vigouroux C, Halbron M, Touati EB, Capel E, Caron-Debarle M, Hartemann A.

Diabetes Care. 2012 Feb;35(2):e4. doi: 10.2337/dc11-1967. No abstract available.

42.

Clinical and metabolic features of adult-onset diabetes caused by ABCC8 mutations.

Riveline JP, Rousseau E, Reznik Y, Fetita S, Philippe J, Dechaume A, Hartemann A, Polak M, Petit C, Charpentier G, Gautier JF, Froguel P, Vaxillaire M.

Diabetes Care. 2012 Feb;35(2):248-51. doi: 10.2337/dc11-1469. Epub 2011 Dec 30.

43.

The Charcot foot in diabetes.

Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, Game F, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L.

J Am Podiatr Med Assoc. 2011 Sep-Oct;101(5):437-46. Review.

PMID:
21957276
44.

The Charcot foot in diabetes.

Rogers LC, Frykberg RG, Armstrong DG, Boulton AJ, Edmonds M, Van GH, Hartemann A, Game F, Jeffcoate W, Jirkovska A, Jude E, Morbach S, Morrison WB, Pinzur M, Pitocco D, Sanders L, Wukich DK, Uccioli L.

Diabetes Care. 2011 Sep;34(9):2123-9. doi: 10.2337/dc11-0844.

45.

Painful diabetic neuropathy: diagnosis and management.

Hartemann A, Attal N, Bouhassira D, Dumont I, Gin H, Jeanne S, Said G, Richard JL; Working Group on the Diabetic Foot from the French-speaking Society of Diabetology.

Diabetes Metab. 2011 Nov;37(5):377-88. doi: 10.1016/j.diabet.2011.06.003. Epub 2011 Aug 4.

PMID:
21820345
46.

Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene.

Bellanné-Chantelot C, Lévy DJ, Carette C, Saint-Martin C, Riveline JP, Larger E, Valéro R, Gautier JF, Reznik Y, Sola A, Hartemann A, Laboureau-Soares S, Laloi-Michelin M, Lecomte P, Chaillous L, Dubois-Laforgue D, Timsit J; French Monogenic Diabetes Study Group.

J Clin Endocrinol Metab. 2011 Aug;96(8):E1346-51. doi: 10.1210/jc.2011-0268. Epub 2011 Jun 15.

PMID:
21677039
47.

Physicians' understanding of patients' personal representations of their diabetes: accuracy and association with self-care.

Sultan S, Attali C, Gilberg S, Zenasni F, Hartemann A.

Psychol Health. 2011 May;26 Suppl 1:101-17. doi: 10.1080/08870441003703226.

PMID:
21337260
48.

Management of patients hospitalized for diabetic foot infection: results of the French OPIDIA study.

Richard JL, Lavigne JP, Got I, Hartemann A, Malgrange D, Tsirtsikolou D, Baleydier A, Senneville E.

Diabetes Metab. 2011 Jun;37(3):208-15. doi: 10.1016/j.diabet.2010.10.003. Epub 2010 Dec 18.

PMID:
21169044
49.

Cognitive and anxiety symptoms in screening for clinical depression in diabetes: a systematic examination of diagnostic performances of the HADS and BDI-SF.

Sultan S, Luminet O, Hartemann A.

J Affect Disord. 2010 Jun;123(1-3):332-6. doi: 10.1016/j.jad.2009.09.022. Epub 2009 Oct 25.

PMID:
19861228
50.

[Anoxia of the newborn].

HARTEMANN AJ.

Concours Med. 1951 Mar 19;73(20):1879-81. Undetermined Language. No abstract available.

PMID:
14831311

Supplemental Content

Loading ...
Support Center